Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
- Conditions
- Depression, Postpartum
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT07047820
A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 52
- Registration Number
- NCT07019064
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 180
- Registration Number
- NCT06962800
- Locations
- 🇺🇸
Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Nephrotex Research Group, Dallas, Texas, United States
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 255
- Registration Number
- NCT06953583
- Locations
- 🇺🇸
UCLA Neurology Outpatient Clinic at Westwood, Los Angeles, California, United States
🇺🇸Norman Fixel Institute for Neurological Diseases UF Health, Gainesville, Florida, United States
🇺🇸USF Health Morsani College of Medicine Department of Neurology, Tampa, Florida, United States
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 454
- Registration Number
- NCT06935357
- Locations
- 🇺🇸
Royal Research, Corp., Hollywood, Florida, United States
🇺🇸Central Florida Kidney Specialists, Orlando, Florida, United States
🇺🇸Applied Research Center of Arkansas, Little Rock, Arkansas, United States
A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 236
- Registration Number
- NCT06741657
- Locations
- 🇺🇸
Las Vegas Clinical Research Unit, Las Vegas, Nevada, United States
🇺🇸Austin Clinical Research Unit, Austin, Texas, United States
A Trial of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR)
- Conditions
- Kidney Transplant Recipients with Late Antibody-Mediated Rejection
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Biogen Idec Research Limited
- Target Recruit Count
- 42
- Registration Number
- 2024-519095-66-00
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Providence Healthcare, Orange, California, United States
A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 25
- Registration Number
- NCT06640933
- Locations
- 🇺🇸
PPD Las Vegas Research Unit, Las Vegas, Nevada, United States
🇺🇸PPD Clinical Research Unit, Austin, Texas, United States
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT06628687
- Locations
- 🇺🇸
Evidera, Morrisville, North Carolina, United States
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 300
- Registration Number
- NCT06623890
- Locations
- 🇺🇸
UCLA Neurology, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of Florida, Gainesville, Florida, United States